The legacy of vigabatrin in a regional epilepsy clinic

Journal of Neurology Neurosurgery and Psychiatry

Volumn 73, Issue 3, 2002, Pages 327-329

  Nicolson, A ^a,b   Leach, J P ^a   Chadwick, D W ^a   Smith, D F ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b Clinical Sciences Centre for Research and Education   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VIGABATRIN;

ANTICONVULSANT THERAPY; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DRUG WITHDRAWAL; EPILEPSY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT COUNSELING; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SEIZURE; TREATMENT OUTCOME; VISUAL FIELD DEFECT;

AMBULATORY CARE FACILITIES; ANTICONVULSANTS; EPILEPSY; FEMALE; HUMANS; MALE; RETROSPECTIVE STUDIES; VIGABATRIN; VISUAL FIELDS;

EID: 0036724077     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.73.3.327     Document Type: Article

References (23)

1. The new antiepileptic drugs: A systematic review of their efficacy and tolerability
2. Severe persistent visual field constriction associated with vigabatrin
3. Severe persistent visual constriction associated with vigabatrin
4. Asymptomatic as well as symptomatic defects occur with vigabatrin
5. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects
6. Characteristics of a unique visual field defect attributed to vigabatrin
7. Visual field defects associated with vigabatrin therapy
8. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication
9. Visual impairment in children with epilepsy treated with vigabatrin
10. Infantile spasms and vigabatrin: Visual field defects may be permanent
11. Visual function loss from vigabatrin: Effect of stopping the drug
12. Vigabatrin visual toxicity: Evolution and dose dependence
13. Visual function is stable in patients who continue long-term vigabatrin therapy: Implications for clinical decision making
14. Recovery of visual field constriction following discontinuation of vigabatrin
15. Another case of reversibility of visual-field defect induced by vigabatrin monotherapy: Is young age a favourable factor?
16. Guideline for prescribing vigabatrin in children has been revised
17. Visual field loss associated with vigabatrin: Quantification and relation to dosage
18. Concentric visual field restriction under vigabatrin therapy: Extent depends on the duration of drug intake
19. Visual field defects with vigabatrin: Epidemiology and therapeutic implications
20. The role of vigabatrin in the management of infantile epileptic syndromes
21. ACTH versus vigabatrin theray in infantile spasms: A retrospective study
22. Is the devil we know the lesser of two evils? Vigabatrin and visual fields